Lotemax® is a powerful anti-inflammatory, clinically proven against multiple causes of ocular inflammation. Based on Investigator's Global Assessment, anterior chamber inflammation was resolved or reasonably controlled by the final visit in 84% of patients using Lotemax.1,2 Back to top In one study, 72% of patients using Lotemax had complete resolution of cells and flare after 4 weeks.4 Back to top Lotemax has been proven effective in giant papillary conjunctivitis (GPC) and seasonal allergic conjunctivitis (SAC).5-8 94% positive response against itching caused by GPC ( n = 220) vs. placebo (79%; n = 219) with p<0.001.7 79% positive response against bulbar injection caused by GPC ( n = 220) vs. placebo (43%; n = 219) with p<0.001.7 94% positive response to prophylactic treatment against signs and symptoms of SAC ( n = 145) vs. placebo (78%; n = 143) with p = 0.001.8 Back to top

Select a product ----------------- Proview IOP Monitor Lotemax Alrex Ocuvite Ocuvite Extra Ocuvite Lutein OptiPranolol Muro 128 Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) offers the broadest range of indications of any ophthalmic steroid currently available. Novel compound with a unique, site-specific mechanism of action Get the answers to your questions about Lotemax Proven effective in clinical studies Impressive safety profile includes a low incidence of IOP elevation Safety Information Package Insert

Nota Legal | Política de Privacidade | © | ™

	1 Stewart R et al. J Cataract Refract Surg. 1998;24:1480-1489. 2 Ophthalmology. 1998; 105:1780-1786. 3 Lotemax [package insert]. 4 Am J Ophthalmol. 1999;127:537-544. 5 Asbell H et al. CLAO J. 1997;23:31-36. 6 Friedlaender MH et al. Am J Ophthalmol. 1997;123:455-464. 7 Data on file. 8 Dell SJ et al. Am J Ophthalmol. 1997;123:791-797.